Depixus receives the Ignite Award at SLAS2024 for its MAGNA™ technology

Depixus, a pioneer in intereactomics, has won the prestigious Society for Laboratory Automation and Screening (SLAS) Ignite Award at the society’s annual International Conference and Exhibition in Boston, MA. The award was presented alongside the unveiling of Depixus’ MAGNA One™ instrument at the conference.

The Ignite Award is given to companies that are revolutionizing the life sciences with their innovative technologies. Participants were evaluated by a panel of experts on various criteria including excellence in innovation, marketing presence, impact, funding, and balanced leadership. Depixus was selected to be one of just 16 companies to participate in the SLAS2024 Innovation AveNEW program, which is a dedicated area for start-ups and emerging companies within the conference. From the 16 companies, the top eight were chosen as finalists for the Ignite Award.

MAGNA One is based on magnetic force spectroscopy, enabling high-throughput analysis of dynamic biomolecular interactions. This technology is the first to offer real-time measurements from thousands of individual molecules simultaneously, making it particularly useful for exploring challenging targets such as RNA and protein-protein interactions. It provides valuable insights into disease mechanisms and accelerates the development of novel therapeutics.

Depixus CEO Gordon Hamilton expressed his excitement about winning the Ignite Award, emphasizing the company’s innovative technology and its potential to impact the understanding and treatment of diseases where new treatments are urgently needed. Chief Commercial Officer Steve Klose added that the timing of the award coincides with the launch of their technology access program and commercial rollout of MAGNA One, marking a significant moment for the company.

For more information about Depixus or their MAGNA One™ instrument, visit depixus.com or contact Steve Klose at steve.klose@depixus.com

By Editor

Leave a Reply